PHM down 1.8%, KBH down 3.5%, LEN down 2.5%. WLH has jumped more than those, so stands to reason on a pullback it would fall more than those.
Excuse me for offering up an opinion, trying to get an intelligent conversation going. Unlike most of the posters on these boards, I didn't personally attack you, make fun of you, etc. Instead, I just offered up a thought. Par for the course for these boards, you responded with sarcasm and derision.
Oil was at $30 on February 11 and is now at about $44. There are many other factors to consider that move the market.
ATHX is a small cap with very low float, not widely held. If fund managers need to raise cash in biotech they would be selling a bit of their Celgene, Gilead, etc. - not ATHX!
It was up 10% yesterday. S&P now down .6% and IBB down 3.3%. ATHX down 3.8%, seems about right.
10:43 AM EDT, 03/17/2016 (MT Newswires) -- Lam Research (LRCX) was initiated coverage by RBC Capital with an outperform rating and price target of $92 a share.
Price: 78.20, Change: +0.39, Percent Change: +0.50
Dude, it's gone up about 60% in about 24 days. And the S&P is down about 1% or so. It would stand to reason that a big mover like WLH would fall further than the market.
Go to the company website, investor relations, news releases - their earnings release includes their complete financials.
As I said on Feb. 6, time will tell. I want to thank all the buyers of my puts at both $5 and $7.50 for the cash. Even yesterday after the announcement, I was able to sell August $7.50 puts for as high #$%$85, net cost of $6.65. Pretty good chance now I will keep all those proceeds!
According to Schwab, they had 7 straight quarters of upside non-GAAP earnings surprises until Q3 '15 when they missed by 16%. Clearly, the markets are expecting another earnings miss upcoming.
You need to look at this in relation to the overall market. The multiple investors are willing to pay for risk assets has ratcheted down significantly since April.
Time will tell. His time horizon is longer than a day or two.
Low analyst target $20, high target $28. Bill Miller calls it a no-brainer buy.